EAM Investors’s Axsome Therapeutics AXSM Stock Holding History

EAM Investors’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.49M	Buy	+26,566	New	+$4.59M	0.52%	70
2025 Q2	–	Sell	-42,222	Closed	-$4.92M	–	241
2025 Q1	$4.92M	Buy	+42,222	New	+$4.81M	0.85%	10
2023 Q3	–	Sell	-18,102	Closed	-$1.3M	–	287
2023 Q2	$1.3M	Buy	+18,102	New	+$1.34M	0.24%	191
2023 Q1	–	Sell	-14,458	Closed	-$1.12M	–	261
2022 Q4	$1.12M	Sell	14,458 -37,634	-72%	-$2.25M	0.23%	207
2022 Q3	$2.32M	Buy	52,092 +932	+2%	+$46.6K	0.51%	74
2022 Q2	$1.96M	Buy	+51,160	New	+$1.62M	0.48%	72
2020 Q3	–	Sell	-29,293	Closed	-$2.41M	–	282
2020 Q2	$2.41M	Sell	29,293 -45,942	-61%	-$3.54M	0.53%	51
2020 Q1	$4.43M	Buy	75,235 +3,679	+5%	+$300K	1.37%	1
2019 Q4	$7.4M	Sell	71,556 -58,028	-45%	-$2.34M	1.63%	1
2019 Q3	$2.62M	Sell	129,584 -18,887	-13%	-$485K	0.69%	31
2019 Q2	$3.82M	Sell	148,471 -78,770	-35%	-$1.58M	0.94%	5
2019 Q1	$3.23M	Buy	+227,241	New	+$2.11M	0.79%	15

Other funds holding AXSM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EAM Investors's AXSM Position: Q1 2026 in Review

EAM Investors opened a new position in Axsome Therapeutics (AXSM) in Q1 2026: 26,566 shares worth $4.49M. The stake represents 0.52% of the portfolio and ranks #70 among its holdings. This is a return to the name: EAM Investors previously reported a position in AXSM as recently as Q1 2025.

EAM Investors first reported a position in AXSM in Q1 2019 and has held it in 12 quarters since. The position peaked at $7.4M in Q4 2019. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

EAM Investors held 26,566 shares of Axsome Therapeutics worth $4.49M as of Q1 2026.
Axsome Therapeutics was a new EAM Investors position in Q1 2026.
Axsome Therapeutics made up 0.52% of EAM Investors's portfolio in Q1 2026, its #70 holding.
EAM Investors first reported a position in Axsome Therapeutics in Q1 2019 and has held it in 12 quarters since.
EAM Investors's Axsome Therapeutics position peaked at $7.4M in Q4 2019.
409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on EAM Investors's 13F filing for Q1 2026, filed 13 May 2026.